These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20536524)

  • 1. Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report.
    Garg R; Hussey C; Ibrahim S
    Diabet Med; 2010 Apr; 27(4):485-6. PubMed ID: 20536524
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
    Matthes J; Faust M
    Dtsch Med Wochenschr; 2008 Oct; 133(43):2233-7. PubMed ID: 18924057
    [No Abstract]   [Full Text] [Related]  

  • 3. [Sitagliptin].
    Taéron C
    Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe leucopenia associated with Sitagliptin use.
    Pitocco D; Zaccardi F; Martini F; Scavone G; Musella T; Caputo S; Ghirlanda G
    Diabetes Res Clin Pract; 2011 Feb; 91(2):e30-2. PubMed ID: 21035885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute pancreatitis following orlistat therapy: report of two cases.
    Ahmad FA; Mahmud S
    JOP; 2010 Jan; 11(1):61-3. PubMed ID: 20065556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sitagliptin combined with sulphonylureas: new indication. Other treatments are preferable.
    Prescrire Int; 2009 Feb; 18(99):14-5. PubMed ID: 19391232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Miller S; St Onge EL
    Ann Pharmacother; 2006; 40(7-8):1336-43. PubMed ID: 16868220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sitagliptin/metformin (Janumet) for type 2 diabetes.
    Med Lett Drugs Ther; 2007 Jun; 49(1262):45-7. PubMed ID: 17541377
    [No Abstract]   [Full Text] [Related]  

  • 10. New treatment for diabetes.
    FDA Consum; 2007; 41(1):3. PubMed ID: 17342826
    [No Abstract]   [Full Text] [Related]  

  • 11. Sitagliptin-associated drug allergy: review of spontaneous adverse event reports.
    Desai S; Brinker A; Swann J; Iyasu S
    Arch Intern Med; 2010 Jul; 170(13):1169-71. PubMed ID: 20625027
    [No Abstract]   [Full Text] [Related]  

  • 12. Elevated hepatic enzymes potentially associated with sitagliptin.
    Gross BN; Cross LB; Foard J; Wood Y
    Ann Pharmacother; 2010 Feb; 44(2):394-5. PubMed ID: 20103614
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
    Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
    [No Abstract]   [Full Text] [Related]  

  • 15. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
    Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].
    Musch A; Heinzl S
    Med Monatsschr Pharm; 2007 Aug; 30(8):282-6; quiz 287-8. PubMed ID: 17879807
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orlistat half the dose without a prescription: new status. In excess body weight: often uncomfortable and don't expect miracles. Frequent gastrointestinal disturbances for a weight loss of a few kilos. Better to encourage dietary measures, exercise and individualised support.
    Prescrire Int; 2009 Jun; 18(101):101. PubMed ID: 19637413
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.